Government of Congo Report issue

Government Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2015
NCT02342171
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

INRB | Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo | Institut National de Research Biomédicale

Active Ingredients

Drugs in Phase 4 Trials (6)

amodiaquine (camoquin) (1 trial)

artemether (1 trial)

artesunate (1 trial)

lumefantrine (Coartem) (1 trial)

mva-bn (JYNNEOS) (1 trial)

vi-dt typhoid conjugate vaccine (1 trial)

Drugs in Phase 3 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Phase 2 Trials (1)

tecovirimat (tpoxx) (1 trial)

Drugs in Other Trials (1)

ANSUVIMAB (Ebanga) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Malaria (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 9